Gyros Protein Technologies introduces Gyrolab AAVX Titer Kit to support cell and gene therapy market
Ready-to-use kit enables rapid adeno-associated virus (AAV) titer determinations during the manufacture of AAV vectors
Ready-to-use kit enables rapid adeno-associated virus (AAV) titer determinations during the manufacture of AAV vectors
Meet the researchers making waves in science and learn about the technologies innovating their research
FoundationOne Liquid CDx analyzes more than 300 cancer-related genes and multiple genomic signatures to inform treatment decisions for all solid tumor cancers
Combining image analysis with structured reporting, the software aims to improve and accelerate the detection of the virus
Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%
The real-time PCR workflow has a capacity of up to 6,000 tests per day per system, and demonstrated 100% agreement with authorized nasopharyngeal assays
QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research
The AI-Rad Companion Brain MR and Prostate MR measures volumetric changes in brain, and segments prostate for targeted biopsy under MRI and ultrasound fusion imaging respectively
The Somatom scanner is equipped with a forward-looking camera and motorized wheels, allowing a single technologist to navigate the device through hospital hallways
Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.
The AccuPlex SARS-CoV-2 molecular controls kit is designed to measure day-to-day assay performance and contains positive materials
The collaboration is the first larger scale production run of Apta-1 as a non-GMP material, intended for use in GLP toxicology studies
The test outperforms other molecular tests with a low detection limit of 15 GEC/reaction (250 GEC/ml of sample) and a robust control system
The consortium aims to determine the dynamics, function and potential for therapeutic intervention of the RNA and protein structures of SARS-CoV-2
IgM assay has 95.51% positive predictive value even when disease incidence is only 3%
The new assays are designed to enable turnaround times for next-generation sequencing results of less than 24 hours
Used to empower clinicians to quickly prescribe treatment regimens for multidrug-resistant TB, the test could help fill a critical gap that is jeopardizing global TB targets
Dr. Jeremy Hirota takes us through the technology behind his translational research program for respiratory health
Nirsevimab is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose
The partnership enables LUMICKS to expand on the implementation of the z-Movi to new immunotherapeutic settings
The new reagent kits aim to make whole genome sequencing more accessible and affordable for labs of all sizes
This powerful new solution aims to provide more accurate COVID-19 antibody detection
Join us on Tuesday, August 11, to learn about a novel serological platform used for COVID-19 testing
Join us on Monday, August 17, to discover solutions for your laboratory's SARS-CoV-2 testing
Join us on Wednesday, August 26, to learn about an alternative assay that aims to identify virus-neutralizing antibodies in as little as five hours